163 related articles for article (PubMed ID: 35205670)
1. Constitutive Activation of p62/Sequestosome-1-Mediated Proteaphagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma.
Quinet G; Xolalpa W; Reyes-Garau D; Profitós-Pelejà N; Azkargorta M; Ceccato L; Gonzalez-Santamarta M; Marsal M; Andilla J; Aillet F; Bosch F; Elortza F; Loza-Alvarez P; Sola B; Coux O; Matthiesen R; Roué G; Rodriguez MS
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205670
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
3. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
[TBL] [Abstract][Full Text] [Related]
4. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
Arkwright R; Pham TM; Zonder JA; Dou QP
Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
[TBL] [Abstract][Full Text] [Related]
5. 3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma.
Feng M; Wang J; Sun M; Li G; Li B; Zhang H
Cancer Cell Int; 2021 May; 21(1):279. PubMed ID: 34039348
[TBL] [Abstract][Full Text] [Related]
6. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
[TBL] [Abstract][Full Text] [Related]
7. Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma.
Kuroda Y; Koyama D; Kikuchi J; Mori S; Ichinohe T; Furukawa Y
Leuk Res; 2021 Dec; 111():106672. PubMed ID: 34332177
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms Regulating the UPS-ALS Crosstalk: The Role of Proteaphagy.
Quinet G; Gonzalez-Santamarta M; Louche C; Rodriguez MS
Molecules; 2020 May; 25(10):. PubMed ID: 32443527
[TBL] [Abstract][Full Text] [Related]
9. Autophagic-lysosomal inhibition compromises ubiquitin-proteasome system performance in a p62 dependent manner in cardiomyocytes.
Tian Z; Wang C; Hu C; Tian Y; Liu J; Wang X
PLoS One; 2014; 9(6):e100715. PubMed ID: 24959866
[TBL] [Abstract][Full Text] [Related]
10. SQSTM1/p62 (sequestosome 1) senses cellular ubiquitin stress through E2-mediated ubiquitination.
Yang J; Peng H; Xu Y; Xie X; Hu R
Autophagy; 2018; 14(6):1072-1073. PubMed ID: 28614034
[TBL] [Abstract][Full Text] [Related]
11. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
[TBL] [Abstract][Full Text] [Related]
13. p62/sequestosome 1 as a regulator of proteasome inhibitor-induced autophagy in human retinal pigment epithelial cells.
Viiri J; Hyttinen JM; Ryhänen T; Rilla K; Paimela T; Kuusisto E; Siitonen A; Urtti A; Salminen A; Kaarniranta K
Mol Vis; 2010 Jul; 16():1399-414. PubMed ID: 20680098
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications.
Alwahsh M; Farhat J; Talhouni S; Hamadneh L; Hergenröder R
EXCLI J; 2023; 22():146-168. PubMed ID: 36998701
[TBL] [Abstract][Full Text] [Related]
15. The Calcineurin-TFEB-p62 Pathway Mediates the Activation of Cardiac Macroautophagy by Proteasomal Malfunction.
Pan B; Li J; Parajuli N; Tian Z; Wu P; Lewno MT; Zou J; Wang W; Bedford L; Mayer RJ; Fang J; Liu J; Cui T; Su H; Wang X
Circ Res; 2020 Jul; 127(4):502-518. PubMed ID: 32366200
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance.
Wu YX; Yang JH; Saitsu H
Oncotarget; 2016 Nov; 7(47):77622-77634. PubMed ID: 27769058
[TBL] [Abstract][Full Text] [Related]
17. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
Sun L; Zhang L; Qian J; Yang J; Yi Q; Dong W; Wang M
Leuk Res; 2012 Mar; 36(3):363-8. PubMed ID: 22000823
[TBL] [Abstract][Full Text] [Related]
18. PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARDBP/TDP-43 proteinopathies.
Lee S; Jeon YM; Cha SJ; Kim S; Kwon Y; Jo M; Jang YN; Lee S; Kim J; Kim SR; Lee KJ; Lee SB; Kim K; Kim HJ
Autophagy; 2020 Aug; 16(8):1396-1412. PubMed ID: 31690171
[TBL] [Abstract][Full Text] [Related]
19. SQSTM1/p62-mediated autophagy compensates for loss of proteasome polyubiquitin recruiting capacity.
Demishtein A; Fraiberg M; Berko D; Tirosh B; Elazar Z; Navon A
Autophagy; 2017 Oct; 13(10):1697-1708. PubMed ID: 28792301
[TBL] [Abstract][Full Text] [Related]
20. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
